Maze Therapeutics (MAZE) Operating Income (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Operating Income data on file, last reported at -$26.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 24.99% year-over-year to -$26.6 million; the trailing twelve-month figure through Mar 2026 stood at -$134.1 million (down 367.04% YoY), and the FY2025 full-year result was -$142.9 million, down 348.15% from the prior year.
• Operating Income rose to -$26.6 million in Q1 2026, from -$38.1 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $139.6 million in Q2 2024 to a low of -$38.1 million in Q4 2025.
• A 3-year average of -$12.4 million and a median of -$29.7 million in 2024 frame the typical range for Operating Income.
• Across the five-year window, Operating Income tumbled 126.14% in 2025 and grew 24.99% in 2026, its largest moves.
• Tracing MAZE's Operating Income over 3 years: stood at -$29.7 million in 2024, then dropped by 28.03% to -$38.1 million in 2025, then soared by 30.23% to -$26.6 million in 2026.
• Business Quant data shows MAZE's Operating Income at -$26.6 million in Q1 2026, -$38.1 million in Q4 2025, and -$33.0 million in Q3 2025.